John Cavanagh
John Cavanagh has worked in behavioral health management and the distribution of medical devices and services for over a decade. In 2014, he facilitated the formation and day-to-day operations of Addison Syndicated Laboratories (ASL), which provided network contracts and improved administrative services for independently owned sleep facilities seeking to join larger hospital-based networks. The success of this model expanded access to therapeutic sleep services for patients in behavioral health, pain management, and primary care.
John has also contributed to the marketing and development of various medical devices. His passion for research and advancing personalized behavioral health—particularly in genetics and neuromodulation—began in 2012. He partnered with others to launch a genetic laboratory in Memphis, Tennessee, and collaborated with Dr. Arturo Taca, M.D., to advance neuromodulation devices for behavioral health and addiction treatment. He contributed to a peer-reviewed study published in the Journal of Alcohol and Drug Abuse.
John was instrumental in pioneering the use of Percutaneous Nerve Field Stimulators (PNFS) for opioid withdrawal, leading to FDA clearance for use in that space. He has also been at the forefront of utilizing Transcranial Magnetic Stimulation (TMS) in the treatment of major depressive disorder. He is an active member of the National TMS Society and a past member of its national insurance committee.
John currently serves on the De Smet Jesuit High School Alumni Board in St. Louis, Missouri. He lives in Dallas, Texas, and enjoys outdoor activities including fishing, hunting, yoga, and ice hockey. Unlimited
subscriptions
start at $89 / Year.
